-
-
Call more information
660-596-2224 -
ASA Monitor November 2023, Vol. 87, 18. Vigil Neuroscience’s Alzheimer’s drug given FDA green light, with a partial clinical hold Vigil Neuroscience has been granted clearance from the FDA to launch an early-stage Alzheimer’s trial, but that approval comes with strings attached: a partial clinical hold. The FDA has approved Vigil’s investigational new drug application for […]
Read MoreAuthor: Ronald G. Pearl, MD, PhD, FASA, FCCM ASA Monitor November 2023, Vol. 87, 26–28. Critical care medicine is an ideal area for the use of artificial intelligence (AI) and machine learning (ML) (Crit Care 2022;26:75). Rounds in the ICU frequently include debates on diagnosis, treatment, prognosis, and the likelihood of patient deterioration. Critical care patients generate […]
Read MoreAuthors: Korina Katsaliaki, PhD et al ASA Monitor November 2023, Vol. 87, 20–21. Machine learning (ML) is a subfield of artificial intelligence (AI) specializing in the development of algorithms and models that enable computers to learn and make predictions or decisions without being explicitly programmed. It involves using statistical methods and computational models for extracting […]
Read MoreAuthors: Julian F. Daza, M.D. et al Anesthesiology October 2023. To the Editor: Postoperative functional impairment is a patient-centered outcome associated with important sequelae such as poor quality of life yet its impact on healthcare expenditure is poorly understood. Such data could shed light on the potential cost savings of interventions that support patients either […]
Read MoreAuthors: Franchesca Arias, PhD et al ASA Monitor November 2023, Vol. 87, 1–6. Since the Roman times, the idea of Pietas – loosely defined as duty, loyalty, or devotion to one’s ancestors or parents – was expressed as an important virtue (asamonitor.pub/487Mxxt). In Asian traditions, filial piety – defined as exhibiting proper love and respect towards one’s parent or elders […]
Read More